Cargando…
Blocking the apoE/Aβ interaction ameliorates Aβ-related pathology in APOE ε2 and ε4 targeted replacement Alzheimer model mice
Accumulation of β-amyloid (Aβ) in the brain is essential to Alzheimer’s disease (AD) pathogenesis. Carriers of the apolipoprotein E (APOE) ε4 allele demonstrate greatly increased AD risk and enhanced brain Aβ deposition. In contrast, APOE ε2 allele carries show reduced AD risk, later age of disease...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4174325/ https://www.ncbi.nlm.nih.gov/pubmed/24972680 http://dx.doi.org/10.1186/s40478-014-0075-0 |
_version_ | 1782336342144843776 |
---|---|
author | Pankiewicz, Joanna E Guridi, Maitea Kim, Jungsu Asuni, Ayodeji A Sanchez, Sandrine Sullivan, Patrick M Holtzman, David M Sadowski, Martin J |
author_facet | Pankiewicz, Joanna E Guridi, Maitea Kim, Jungsu Asuni, Ayodeji A Sanchez, Sandrine Sullivan, Patrick M Holtzman, David M Sadowski, Martin J |
author_sort | Pankiewicz, Joanna E |
collection | PubMed |
description | Accumulation of β-amyloid (Aβ) in the brain is essential to Alzheimer’s disease (AD) pathogenesis. Carriers of the apolipoprotein E (APOE) ε4 allele demonstrate greatly increased AD risk and enhanced brain Aβ deposition. In contrast, APOE ε2 allele carries show reduced AD risk, later age of disease onset, and lesser Aβ accumulation. However, it remains elusive whether the apoE2 isoform exerts truly protective effect against Aβ pathology or apoE2 plays deleterious role albeit less pronounced than the apoE4 isoform. Here, we characterized APP(SW)/PS1(dE9)/APOE ε2-TR (APP/E2) and APP(SW)/PS1(dE9)/APOE ε4-TR (APP/E4) mice, with targeted replacement (TR) of the murine Apoe for human ε2 or ε4 alleles, and used these models to investigate effects of pharmacological inhibition of the apoE/Aβ interaction on Aβ deposition and neuritic degeneration. APP/E2 and APP/E4 mice replicate differential effect of human apoE isoforms on Aβ pathology with APP/E4 mice showing a several-fold greater load of Aβ plaques, insoluble brain Aβ levels, Aβ oligomers, and density of neuritic plaques than APP/E2 mice. Furthermore, APP/E4 mice, but not APP/E2 mice, exhibit memory impairment on object recognition and radial arm maze tests. Between the age of 6 and 10 months APP/E2 and APP/E4 mice received treatment with Aβ12-28P, a non-toxic, synthetic peptide homologous to the apoE binding motif within the Aβ sequence, which competitively blocks the apoE/Aβ interaction. In both lines, the treatment significantly reduced brain Aβ accumulation, co-accumulation of apoE within Aβ plaques, and neuritic degeneration, and prevented memory deficit in APP/E4 mice. These results indicate that both apoE2 and apoE4 isoforms contribute to Aβ deposition and future therapies targeting the apoE/Aβ interaction could produce favorable outcome in APOE ε2 and ε4 allele carriers. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s40478-014-0075-0) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4174325 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-41743252014-09-26 Blocking the apoE/Aβ interaction ameliorates Aβ-related pathology in APOE ε2 and ε4 targeted replacement Alzheimer model mice Pankiewicz, Joanna E Guridi, Maitea Kim, Jungsu Asuni, Ayodeji A Sanchez, Sandrine Sullivan, Patrick M Holtzman, David M Sadowski, Martin J Acta Neuropathol Commun Research Accumulation of β-amyloid (Aβ) in the brain is essential to Alzheimer’s disease (AD) pathogenesis. Carriers of the apolipoprotein E (APOE) ε4 allele demonstrate greatly increased AD risk and enhanced brain Aβ deposition. In contrast, APOE ε2 allele carries show reduced AD risk, later age of disease onset, and lesser Aβ accumulation. However, it remains elusive whether the apoE2 isoform exerts truly protective effect against Aβ pathology or apoE2 plays deleterious role albeit less pronounced than the apoE4 isoform. Here, we characterized APP(SW)/PS1(dE9)/APOE ε2-TR (APP/E2) and APP(SW)/PS1(dE9)/APOE ε4-TR (APP/E4) mice, with targeted replacement (TR) of the murine Apoe for human ε2 or ε4 alleles, and used these models to investigate effects of pharmacological inhibition of the apoE/Aβ interaction on Aβ deposition and neuritic degeneration. APP/E2 and APP/E4 mice replicate differential effect of human apoE isoforms on Aβ pathology with APP/E4 mice showing a several-fold greater load of Aβ plaques, insoluble brain Aβ levels, Aβ oligomers, and density of neuritic plaques than APP/E2 mice. Furthermore, APP/E4 mice, but not APP/E2 mice, exhibit memory impairment on object recognition and radial arm maze tests. Between the age of 6 and 10 months APP/E2 and APP/E4 mice received treatment with Aβ12-28P, a non-toxic, synthetic peptide homologous to the apoE binding motif within the Aβ sequence, which competitively blocks the apoE/Aβ interaction. In both lines, the treatment significantly reduced brain Aβ accumulation, co-accumulation of apoE within Aβ plaques, and neuritic degeneration, and prevented memory deficit in APP/E4 mice. These results indicate that both apoE2 and apoE4 isoforms contribute to Aβ deposition and future therapies targeting the apoE/Aβ interaction could produce favorable outcome in APOE ε2 and ε4 allele carriers. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s40478-014-0075-0) contains supplementary material, which is available to authorized users. BioMed Central 2014-06-28 /pmc/articles/PMC4174325/ /pubmed/24972680 http://dx.doi.org/10.1186/s40478-014-0075-0 Text en © Pankiewicz et al.; licensee BioMed Central Ltd. 2014 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Pankiewicz, Joanna E Guridi, Maitea Kim, Jungsu Asuni, Ayodeji A Sanchez, Sandrine Sullivan, Patrick M Holtzman, David M Sadowski, Martin J Blocking the apoE/Aβ interaction ameliorates Aβ-related pathology in APOE ε2 and ε4 targeted replacement Alzheimer model mice |
title | Blocking the apoE/Aβ interaction
ameliorates Aβ-related pathology in APOE ε2 and ε4 targeted replacement
Alzheimer model mice |
title_full | Blocking the apoE/Aβ interaction
ameliorates Aβ-related pathology in APOE ε2 and ε4 targeted replacement
Alzheimer model mice |
title_fullStr | Blocking the apoE/Aβ interaction
ameliorates Aβ-related pathology in APOE ε2 and ε4 targeted replacement
Alzheimer model mice |
title_full_unstemmed | Blocking the apoE/Aβ interaction
ameliorates Aβ-related pathology in APOE ε2 and ε4 targeted replacement
Alzheimer model mice |
title_short | Blocking the apoE/Aβ interaction
ameliorates Aβ-related pathology in APOE ε2 and ε4 targeted replacement
Alzheimer model mice |
title_sort | blocking the apoe/aβ interaction
ameliorates aβ-related pathology in apoe ε2 and ε4 targeted replacement
alzheimer model mice |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4174325/ https://www.ncbi.nlm.nih.gov/pubmed/24972680 http://dx.doi.org/10.1186/s40478-014-0075-0 |
work_keys_str_mv | AT pankiewiczjoannae blockingtheapoeabinteractionamelioratesabrelatedpathologyinapoee2ande4targetedreplacementalzheimermodelmice AT guridimaitea blockingtheapoeabinteractionamelioratesabrelatedpathologyinapoee2ande4targetedreplacementalzheimermodelmice AT kimjungsu blockingtheapoeabinteractionamelioratesabrelatedpathologyinapoee2ande4targetedreplacementalzheimermodelmice AT asuniayodejia blockingtheapoeabinteractionamelioratesabrelatedpathologyinapoee2ande4targetedreplacementalzheimermodelmice AT sanchezsandrine blockingtheapoeabinteractionamelioratesabrelatedpathologyinapoee2ande4targetedreplacementalzheimermodelmice AT sullivanpatrickm blockingtheapoeabinteractionamelioratesabrelatedpathologyinapoee2ande4targetedreplacementalzheimermodelmice AT holtzmandavidm blockingtheapoeabinteractionamelioratesabrelatedpathologyinapoee2ande4targetedreplacementalzheimermodelmice AT sadowskimartinj blockingtheapoeabinteractionamelioratesabrelatedpathologyinapoee2ande4targetedreplacementalzheimermodelmice |